Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.
EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.
An Avastin combination draws a blank in the Imagyn-050 study. Will a combo with a Parp inhibitor fare any better?
Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
Close analysis of the Parp inhibitor’s pivotal prostate cancer trial raises additional questions over this week’s US approval.
An unexpectedly broad prostate cancer label gives the Parp inhibitor a strong advantage over Clovis’s rival Rubraca.
Astrazeneca’s Lynparza is due US approval decisions in prostate and ovarian cancers, while Bristol's Opdivo’s fate will be determined in lung cancer.